BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could treat obesity...
BioCentury | Feb 23, 2021
Distillery Therapeutics

Mir690, NADK as targets in insulin resistance

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes; obesity Mimicking Mir690 or inhibiting its target, NADK mRNA, could treat insulin resistance associated with obesity and Type II diabetes. A synthetic Mir690 mimic or an siRNA against NADK increased...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

After securing $40 million in its first institutional round this week, HemoShear will make the next step in its evolution from service play to drug developer with in-house metabolic disease programs in Phase II testing. ...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat NASH and liver fibrosis. Chemical synthesis of analogs of adiponectin’s globular domain yielded a peptide...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

The migration of new modalities into prevalent indications took another step forward on Friday with the European Commission’s approval of Novartis’ siRNA therapy Leqvio inclisiran to treat hypercholesterolemia...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

As Barry Greene departs Alnylam, he believes the modality he nurtured from plan to reality has the potential to sit alongside mAbs and small molecules as an agent of choice. Greene announced in August...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking a lipid hydrolase for liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Inhibiting ASAH1, an enzyme that hydrolyzes ceramide, could treat liver fibrosis. In patients with chronic HCV infection, levels of ASAH1 in hepatic stellate cells were higher in...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

DISEASE CATEGORY: Endocrine/metabolic; musculoskeletal INDICATION: Obesity; musculoskeletal Promoting adenosine signaling through ADORA2B could treat obesity and aging-induced sarcopenia. In brown adipose tissue biopsies from lean and overweight individuals, ADORA2B expression was lower in older individuals...
Items per page:
1 - 10 of 1381